Using ATR inhibitors to overcome resistance to PARP inhibitors in ovarian cancer
ATR inhibitor-mediated reversal of PARP inhibitor resistance in high-grade serous ovarian cancer (HGSOS)
This study is looking at how a new drug called AZD6738 can help make ovarian cancer treatments work better for patients with BRCA mutations who have stopped responding to their current therapies, with the hope of finding a combination that can be tested in future clinical trials.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10895321 on NIH RePORTER |
What this research studies
This research investigates how ATR inhibitors can help reverse resistance to PARP inhibitors in patients with high-grade serous ovarian cancer (HGSOC), particularly those with BRCA mutations. The approach involves testing the ATR inhibitor AZD6738 both alone and in combination with the PARP inhibitor olaparib in various models, including patient-derived xenografts. The goal is to identify effective treatment combinations that restore the cancer's sensitivity to therapy, ultimately leading to a clinical trial for patients who have developed resistance to current treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with high-grade serous ovarian cancer who have BRCA mutations and have experienced resistance to PARP inhibitors.
Not a fit: Patients without BRCA mutations or those who have not been treated with PARP inhibitors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide new treatment options for patients with ovarian cancer who have become resistant to existing therapies.
How similar studies have performed: Other research has shown promising results with similar approaches, indicating potential for success in this area.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Shapiro, Geoffrey I — Dana-Farber Cancer Inst
- Study coordinator: Shapiro, Geoffrey I
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.